25/03/2015 MUMBAI: Dilip Shanghvi, Managing Director, Sun Pharma at a press convention held in Mumbai on March 25, 2015. Photo : Paul Noronha
| Photo Credit: PAUL NORONHA
Sun Pharmaceutical Industries Ltd. reported that its fourth quarter consolidated net profit grew to ₹1,984.5 crore in contrast with net lack of ₹2,277.3 crore in the identical interval final yr, because of improved efficiency.
Gross gross sales at ₹10,725.6 crore grew 14.3% Year on Year (YoY), the corporate stated in a press launch.
India formulation gross sales at ₹3,364.1 crore was up 8.7% YoY and US formulation gross sales at $430 million was up 10.5% in contrast with Q4 final yr, it stated.
Emerging Markets formulation gross sales at $221 million, was up 7.5% whereas Rest of World formulation gross sales at $191 million was up 7.4% YoY, the corporate added.
For the monetary yr ended March 31, 2023 the corporate reported a net profit of ₹8,473.6 crore in contrast with ₹3,272.7 crore final yr.
Gross gross sales at ₹43,278.9 crore grew 12.6% over the identical interval final yr.
The Board has proposed a ultimate dividend of ₹4 per share for the yr FY23. This is along with the interim dividend of ₹7.5 per share paid in FY23, taking the full dividend for FY23 to ₹11.5 per share in comparison with ₹10 per share for FY22.
Dilip Shanghvi, Managing Director of the Company stated, “I am pleased with well-rounded growth demonstrated in FY23 by the company. Several of our businesses including Specialty, India and Emerging markets have continued to progress well.”
“Our Specialty business remains on growth path and we are committed to continue scaling it up. Acquisition of Concert helps further strengthen our portfolio in dermatology,” he stated.
